Navigation Links
Pharmos Corporation Reports 2011 Fourth Quarter and Full Year Results
Date:2/17/2012

31, 2011, the Company had approximately $1.5 million in cash and cash equivalents which is expected to be sufficient to fund current operations, through at least June of 2012 including the Gout trial.

Twelve-months Ended December 31, 2011For the twelve months ended December 31, 2011, Pharmos recorded a net loss of $2.0 million, or $0.03 per share compared to a net loss of $1.5 million, or $0.03 per share for the twelve months ended December 31, 2010.  

During the year, the Company conducted work in preparation for initiating a proof-of-concept trial in Gout patients using Levotofisopam and also incurred costs related to manufacturing capsules needed for this trial. Additionally, costs were incurred related to conducting a non-human primate toxicology study. At the end of 2011, the Company paid for some preliminary administrative costs for the start of the Gout trial in 2012. On a G&A basis the Company was able to reduce the overall spending in comparison to 2010.

Net Research & development (R&D) expenses increased by $617,136 or 244% from $253,456 in 2010 to $870,592 in 2011 due to the addition of research and development activities on a proof-of-concept trial in Gout patients using Levotofisopam. The increase was reflected in virtually every research and development category. The primary additions include an $112,000 increase in professional fees and consulting and a $355,000 increase in clinical fees which was offset by a reduction of $94,000 in various facility related expenses. The Company received a $244,000 cash grant in 2010 under the Federal Qualifying Therapeutic Discovery Project for work completed on Dextofisopam in 2009. Consulting and professional fees increased substantially as the Company conducted work in preparation for initiating a proof-of-concept trial in Gout patients using Levotofisopam in the first half of the year.
Clinical study fees increased due to costs related to manufacturing capsules needed
'/>"/>

SOURCE Pharmos Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmos Corporation Reports 2011 Second Quarter Results
2. Pharmos Corporation Reports 2010 Third Quarter Results
3. Pharmos Corporation Reports Fourth Quarter and Full Year 2009 Results
4. Pharmos Corporation Reports 2009 Third Quarter Results
5. Pharmos Issues Business Update on Dextofisopam Trial and Financing
6. Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
7. Angeion Corporation to Report First Quarter Fiscal 2012 Financial Results on Tuesday, February 28, 2012
8. Celladon Corporation Completes $43 Million Financing to Advance MYDICAR® for the Treatment of Heart Failure
9. Unilife Corporation Announces Financial Results for Fiscal Year 2012 Second Quarter
10. Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
11. Luminex Corporation Reports Fourth Quarter and Full Year 2011 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... -- Digirad Corporation (Nasdaq: DRAD) today announced that it has sent ... ), a healthcare commercialization services company, responding to PDI,s ... Digirad calls upon PDI to immediately ... operate in the ordinary course of business and to ... on acquisitions or other extraordinary transactions. Digirad believes that ...
(Date:10/31/2014)... , Oct. 31, 2014  Semler Scientific, ... emerging medical risk assessment company that develops patented ... and evaluating chronic diseases, today reported financial results ... September 30, 2014. "In the ... Doug Murphy-Chutorian , M.D., chief executive officer ...
(Date:10/31/2014)... October 31, 2014 Investor-Edge has initiated ... MDT ), Abbott Laboratories (NYSE: ABT ), Hologic ... RMD ), and Covidien PLC (NYSE: COV). Free research ... . The US markets on Thursday, October 30, ... Industrial Average finished at 17,195.42, up 1.30% and the NASDAQ ...
Breaking Medicine Technology:Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 2Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 3Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 4Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 5Semler Reports Third Quarter 2014 Financial Results 2Semler Reports Third Quarter 2014 Financial Results 3Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 2Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 3Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 4Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien 5
... 2010 Reportlinker.com announces that a new market research ... Toxicology and Pharmacology http://www.reportlinker.com/p0324751/Toxicology-and-Pharmacology.html ... Regulation; Technical, Political and Economic Challenges – key report ... are almost exclusively outsourced and the market is worth ...
... Nov. 3, 2010 Breast Cancer Action (BCA) learned today ... Lilly & Company via a billboard in Indianapolis have ... sick.  Tell them to stop" was rejected by every ... working within the guidelines of each billboard company contacted, ...
Cached Medicine Technology:Reportlinker Adds Toxicology and Pharmacology 2Reportlinker Adds Toxicology and Pharmacology 3Breast Cancer Message Barred in Eli Lilly's Hometown 2
(Date:10/31/2014)... Oct. 31, 2014 (HealthDay News) -- Access to generic ... patients will stick with their drug treatment, a new ... women with hormone receptor-positive breast cancer can reduce recurrence ... Hershman, an associate professor of epidemiology at Columbia University ... hospital news release. "However, work by our ...
(Date:10/31/2014)... Alan Mozes HealthDay ... In the world of 21st-century medicine, organ transplantation is nothing ... followed by the first liver transplant in 1963 and the ... even managed the transplantation of a patient,s entire face. ... entire human eye. But if one team of U.S. scientists ...
(Date:10/31/2014)... Each year, people across the United States spend an ... friends, which costs $522 billion, according to new research. ... on the time and wages that caregivers give up ... in daily activities. The study authors said the significant ... workplace flexibility policies. "Our findings provide a new ...
(Date:10/30/2014)... at Albert Einstein College of Medicine ... will present their latest aging research at ... Scientific Meeting. Topics include the identification of a ... cognitive impairment and the cellular biology of aging. ... in Washington, D.C., "Einstein-Montefiore has distinguished itself in ...
(Date:10/30/2014)... Tanaka and her research group at the DFG Research ... at the TU Dresden (CRTD) demonstrated for the first ... spinal cord in three dimensions from mouse embryonic stem ... dorsal interneurons along the dorsal/ventral axis was observed., This ... " Stem Cell Reports " on 30.10.2014 ., ...
Breaking Medicine News(10 mins):Health News:Generic Drugs May Help Breast Cancer Patients Stick to Therapy 2Health News:Scientists Set Their Sights on First Whole-Eye Transplant 2Health News:Scientists Set Their Sights on First Whole-Eye Transplant 3Health News:'Informal Care' for Older Americans Tops $500B Annually, Study Finds 2Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 2Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 3Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 4Health News:Reconstruction of a patterned piece of spinal cord in 3-D culture 2
... 30 Keck Graduate Institute (KGI) ... begin in January 2010, for those with an undergraduate degree ... skills before applying to medical school. , "We,re excited to ... medical professional," says Sheldon M. Schuster, PhD, KGI,s president. "Whether ...
... BEIJING, Sept. 30 /PRNewswire-Asia/ -- Sinovac Biotech ... products in China, announced today that,Sinovac has received its ... Ministry of Industry and Information Technology of the People,s,Republic ... purchase order,Sinovac is required to produce an additional 3 ...
... America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord ... ) focused on bringing the life saving potential ... nationwide and internationally, said today that it is opening ... laboratory in Las Vegas, as planned, the first ...
... National Breast Cancer Awareness Month and Topcor is introducing a ... October 5th, "Clipa for a Cure" is a special edition ... donate 10% of the retail price of every pink Clipa ... Society, breast cancer is the second leading cause of cancer ...
... Americans lack confidence that healthcare reform will deliver ... a survey released today by Thomson Reuters. , Forty-one ... make healthcare more affordable. When sorted by political ... divisions along party lines: 72 percent of Democrats said ...
... , LUDWIGSHAFEN, Germany, September 30 ... to cope with all the sustenance,we shove into it every ... the hardest substance that the human body produces. It consists ... questions of our Podcast listeners on Chemistry in our,everyday life. ...
Cached Medicine News:Health News:KGI Establishes Post Baccalaureate Premedical Program 2Health News:Sinovac Obtains Second Order of H1N1 Vaccine from Chinese Central Government 2Health News:Sinovac Obtains Second Order of H1N1 Vaccine from Chinese Central Government 3Health News:Cord Blood America Opens Las Vegas Cryogenic Laboratory; Consolidates Offices in Nevada 2Health News:Cord Blood America Opens Las Vegas Cryogenic Laboratory; Consolidates Offices in Nevada 3Health News:'Clipa for a Cure': New Pink Instant Handbag Hanger Benefits Breast Cancer Research 2Health News:Thomson Reuters Survey: Americans Skeptical That Healthcare Reform Will Improve Quality or Affordability 2Health News:BASF Podcast: The Chemical Reporter - Why Does Fluoride Make Your Teeth Hard? 2Health News:BASF Podcast: The Chemical Reporter - Why Does Fluoride Make Your Teeth Hard? 3
This cannula's patented tip allows the simultaneous infusion of cardioplegia and aspiration of air from the aorta...
This cannula features a PVC body, auto inflatable smooth cuff, pressure monitoring line with integral stopcock....
...
... Select CAP® cannulae provides a simple ... readings. An innovative combination of aortic ... line, the Select CAP® can provide ... arterial pressure readings on which you ...
Medicine Products: